Efficacy and Safety of Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Update From a Pivotal Open-label Study With a Median Follow-up of ≥2.5 Years

Nikhil I. Khushalani, MD, of Moffitt Cancer Center in Tampa, Florida, reviews updated efficacy and safety results from the pivotal open-label study of cosibelimab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, with a median follow-up of at least 2.5 years, as presented at the 2026 ESMO Congress.